Summary (tl;dr)

Vitruvias Therapeutics has issued a nationwide recall for one lot of its Thyroid Tablets, USP 30 mg, due to concerns that the medication may be superpotent and could lead to hyperthyroidism.

Essential Background

Thyroid Tablets, USP, are a medication derived from porcine thyroid glands used to treat hypothyroidism, an underactive thyroid condition. They contain both levothyroxine and liothyronine, essential thyroid hormones. Patients rely on these tablets to maintain proper thyroid hormone levels in their bodies.

The Full Story

Vitruvias Therapeutics Inc. voluntarily initiated a recall of a specific lot (Lot. No. 504950) of its Thyroid Tablets, USP 30 mg, on August 21, 2026. The U.S. Food and Drug Administration (FDA) publicly announced this recall on August 24, 2026, after testing revealed the potential for the product to be "superpotent," meaning it could contain an excessive amount of thyroid hormone. This particular lot was distributed nationwide across the USA to Vitruvias Therapeutics' direct accounts between January 31, 2025, and September 30, 2025.

Why It Matters

Consumption of superpotent thyroid tablets can lead to hyperthyroidism, an overactive thyroid condition, which can manifest with symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, and heart rhythm disturbances. The elderly, pregnant women, and infants are particularly at a higher risk for adverse outcomes, including cardiac issues in older adults and maternal and fetal complications, such as premature delivery and low birth weight, in pregnant women. Overtreatment in infants can also negatively impact their growth and development. While Vitruvias Therapeutics has not yet received reports of adverse events related to this specific recall, patients currently taking medication from the affected lot are advised to contact their healthcare provider for guidance before discontinuing use.

Geographic Location

• Auburn, Lee County, Alabama, United States (location of Vitruvias Therapeutics headquarters and origin of recall announcement)
• United States (nationwide distribution of recalled product)